Sign in

CIK 0001395937

  • Large accelerated filer

Syndax Pharmaceuticals Inc

Sign in to watch
Ticker
SNDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
320162505
Phone
+1 781-419-1400
Business address
730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
  1. 4 Planned sale Director sold 57,600 shares at an average $15.19 ($875,100)
  2. 4 Other acquisition Chief Financial Officer acquired 1,226 shares (other)
  3. 4 Open-market sale Chief Financial Officer sold 1,296 shares at $9.29 ($12,033)
  4. 4 Open-market sale Chief Executive Officer sold 7,534 shares at $9.29 ($69,953)
  5. 4 Open-market buy Chief Financial Officer bought 3,000 shares
  6. 4 Open-market buy Head of R&D, CMO bought 11,765 shares at $9.00 ($105,826)
  7. 4 Open-market buy Director bought 5,000 shares at $8.99 ($44,950)
  8. 4 Open-market buy Director bought 10,000 shares at $9.11 ($91,120)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Exercise or conversion Chief Executive Officer acquired 6,074 shares (option exercise)
  11. 4 Planned sale Chief Executive Officer sold 7,814 shares at $15.05 ($117,564)
  12. 4 Open-market sale Chief Financial Officer sold 3,777 shares at $15.50 ($58,559)
  13. 4 Open-market sale Chief Executive Officer sold 13,288 shares at $15.50 ($206,017)
  14. 4 Open-market sale President, Head of R&D sold 4,618 shares at $15.50 ($71,597)
  15. 4 Grant or award President, Head of R&D acquired 41,900 shares (grant or award)
  16. 4 Grant or award Chief Financial Officer acquired 41,900 shares (grant or award)
  17. 4 Grant or award Chief Executive Officer acquired 149,500 shares (grant or award)
  18. 4 Grant or award Director acquired 50,000 shares (grant or award)
  19. 4 Grant or award Director acquired 25,000 shares (grant or award)
  20. 4 Grant or award Director acquired 25,000 shares (grant or award)

Page 2 of 13 · 259 filings